logo

For the Inventor, By the Inventor

Brussels, Belgium

Ucbbiopharma Srl


USPTO Granted Patents = 129

% Expired Patents = 5.4



Trademarks = 53

Forward Citations = 85

Loading Chart...
Loading Chart...

250 inventors (with patents filed for the assignee):

goldMedal Kerry Louise Tyson (16 out of 42 patents)

silverMedal Daniel John Lightwood (15 out of 21 patents)

bronzeMedal Stephen Edward Rapecki (13 out of 29 patents)

4.  Jag Paul Heer (13 out of 21 patents)

5.  Timothy John Norman (13 out of 26 patents)

6.  Terence Seward Baker (12 out of 36 patents)

7.  Sam Philip Heywood (11 out of 26 patents)

8.  Ralph Adams (11 out of 41 patents)

9.  David Paul Humphreys (10 out of 46 patents)

10.  David James McMillan (10 out of 12 patents)

11.  James Philip O'Connell (10 out of 10 patents)

12.  John Robert Porter (10 out of 67 patents)

13.  Michael John Wright (9 out of 18 patents)

14.  Alastair Lawson (9 out of 12 patents)

15.  Laurent Provins (8 out of 16 patents)


Core Competencies:
Multi-Specific Antibodies
Protein Purification
IL-17 Modulators
Anti-Alpha-Synuclein Antibodies
Gremlin-1 Inhibitors
Humanized Antibodies
Pharmaceutical Compositions
Cell Culture Methods
Antibody Design
Medical Imaging
Antibody Therapeutics
Drug Delivery

129 patents:

1. 12735396 - Dihydro-cyclopenta-isoquinoline (2026-09-15),
2. 12692304 - ANTIBODIES AGAINST INTERLEUKIN-22 (2026-07-28),
3. 12679829 - Fused imidazole derivatives as IL-17 modulators (2026-07-14),
4. 12673992 - BISPECIFIC ANTIBODIES AGAINST CD9 AND CD7 (2026-07-07),
5. 12662475 - Difluorocyclohexyl derivatives as IL-17 modulators (2026-06-23),
6. 12662455 - Tetrahydrobenzo-quinoline sulfonamide derivatives useful as IgE modulators (2026-06-23),
7. 12649754 - Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone (2026-06-09),
8. 12649726 - Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator (2026-06-09),
9. 12643896 - Dicyclopropylmethyl derivatives as IL-17 modulators (2026-06-02),
10. 12643877 - Substituted tetrahydroisoquinoiline derivative as a D1 positive allosteric modulator (2026-06-02),
11. 12637507 - ANTIBODY WITH BINDING SPECIFICITY FOR HUMAN IL-13 (2026-05-26),
12. 12630647 - ANTIBODIES AGAINST KLK5 (2026-05-19),
13. 12617786 - Dihydro-cyclopenta-isoquinoline sulfonamides derivatives (2026-05-05),
14. 12583638 - Method for filling vials containing liquid drug products (2026-03-24),
15. 12577228 - Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds (2026-03-17),
Ucbbiopharma Srl, based in Brussels, specializes in the development of innovative antibody therapeutics. The company focuses on advanced technologies such as multi-specific antibodies and protein purification methods, addressing critical therapeutic areas including IL-17 modulation and neurodegenerative diseases through anti-alpha-synuclein antibodies. Ucbbiopharma is committed to enhancing treatment options with humanized antibodies and pharmaceutical compositions, leveraging sophisticated cell culture techniques to drive research and development in the biopharmaceutical sector.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

129 Patents

#11 in Brussels

#38 in Belgium

#6,214 in the World

Brussels, BE
Brussels, Belgium

Ucbbiopharma Srl

Forward Citations = 85

250 inventors:

goldMedal Kerry Louise Tyson (16 out of 42 patents)

silverMedal Daniel John Lightwood (15 out of 21 patents)

bronzeMedal Stephen Edward Rapecki (13 out of 29 patents)

4.  Jag Paul Heer (13 out of 21 patents)

5.  Timothy John Norman (13 out of 26 patents)

Please report any incorrect information to [email protected]
Loading…